CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 176 filers reported holding CLOVIS ONCOLOGY INC in Q4 2016. The put-call ratio across all filers is 0.75 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $633,000 | -95.5% | 99,485 | -97.2% | 0.02% | -96.2% |
| Q3 2019 | $14,179,000 | -72.5% | 3,607,800 | +4.2% | 0.47% | -67.5% |
| Q2 2019 | $51,484,000 | -54.6% | 3,462,300 | -24.1% | 1.46% | -56.0% |
| Q1 2019 | $113,277,000 | +55.3% | 4,563,929 | +12.4% | 3.31% | +13.0% |
| Q4 2018 | $72,927,000 | +39.6% | 4,060,529 | +128.3% | 2.93% | +82.5% |
| Q3 2018 | $52,229,000 | -34.7% | 1,778,300 | +1.1% | 1.61% | -40.8% |
| Q2 2018 | $79,964,000 | -10.9% | 1,758,600 | +33.2% | 2.72% | -30.4% |
| Q4 2017 | $89,762,000 | +9.3% | 1,320,027 | +32.5% | 3.90% | -3.7% |
| Q3 2017 | $82,121,000 | -4.3% | 996,610 | +8.8% | 4.05% | -22.4% |
| Q2 2017 | $85,802,000 | +38.5% | 916,389 | -5.8% | 5.22% | +29.9% |
| Q1 2017 | $61,932,000 | -14.0% | 972,696 | -40.0% | 4.02% | -35.2% |
| Q4 2016 | $71,976,000 | -2.6% | 1,620,355 | -21.0% | 6.20% | +5.5% |
| Q3 2016 | $73,902,000 | +73.9% | 2,049,985 | -33.8% | 5.88% | +44.8% |
| Q2 2016 | $42,503,000 | -28.6% | 3,097,850 | -0.0% | 4.06% | -33.3% |
| Q1 2016 | $59,507,000 | -5.3% | 3,099,336 | +72.6% | 6.09% | +29.5% |
| Q4 2015 | $62,858,000 | -28.6% | 1,795,936 | +87.5% | 4.70% | -29.5% |
| Q3 2015 | $88,064,000 | +31.9% | 957,634 | +26.1% | 6.67% | +22.0% |
| Q2 2015 | $66,743,000 | -0.2% | 759,479 | -15.7% | 5.47% | -8.9% |
| Q1 2015 | $66,872,000 | +65.5% | 900,879 | +24.8% | 6.00% | +36.5% |
| Q4 2014 | $40,411,000 | +13.6% | 721,632 | -8.0% | 4.40% | +7.1% |
| Q3 2014 | $35,583,000 | +18.7% | 784,459 | +8.4% | 4.11% | +13.1% |
| Q2 2014 | $29,973,000 | -15.7% | 723,816 | +41.0% | 3.64% | -14.3% |
| Q1 2014 | $35,549,000 | +3.1% | 513,198 | -10.3% | 4.24% | -0.3% |
| Q4 2013 | $34,491,000 | +20.4% | 572,270 | +21.4% | 4.26% | -1.4% |
| Q3 2013 | $28,648,000 | -10.0% | 471,345 | -0.8% | 4.32% | -23.1% |
| Q2 2013 | $31,841,000 | +123.3% | 475,377 | -4.4% | 5.61% | +114.4% |
| Q1 2013 | $14,257,000 | – | 497,277 | – | 2.62% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 814,833 | $60,485,054,000 | 53.20% |
| Palo Alto Investors LP | 2,121,857 | $157,505,000 | 7.79% |
| NEA Management Company, LLC | 2,279,781 | $169,228,000 | 7.65% |
| EcoR1 Capital, LLC | 243,048 | $18,041,000 | 6.01% |
| Redmile Group, LLC | 900,879 | $66,872,000 | 6.00% |
| Opaleye Management Inc. | 140,000 | $10,392,000 | 4.82% |
| PFM Health Sciences, LP | 2,266,756 | $168,261,000 | 4.64% |
| Partner Investment Management, L.P. | 40,798 | $3,028,000 | 4.56% |
| CLIFTON PARK CAPITAL MANAGEMENT, LLC | 826,919 | $61,383,000 | 3.74% |
| Opus Point Partners Management, LLC | 55,988 | $4,156,000 | 3.48% |